Immix Biopharma presented positive phase 2 results for NXC-201 at ASH 2025, showing a complete response rate of 75% by independent review committee.
MRD negativity in bone marrow predicts future complete responses, potentially increasing future CR rate to 95%.
NEXICART-2 final readout and BLA submission planned for 2026.
Complete Response Rate
NXC-201 demonstrated a 75% complete response rate in phase 2 trials, with potential to reach 95% with MRD negativity in bone marrow.
Clinical Improvement
70% of evaluable patients showed downstream clinical improvement after NXC-201 treatment.
Market Potential
Growing AL Amyloidosis market, with the number of patients estimated to reach 38,500 in 2026 and market value expected to reach $6 billion by 2025.
- NXC-201's positive results indicate a significant advancement in treating relapsed/refractory AL Amyloidosis.
- The potential for higher future complete response rates and the planned BLA submission in 2026 position Immix Biopharma as a leading player in the field.
Immix Biopharma's successful phase 2 results for NXC-201 mark a significant milestone in addressing the unmet medical need in AL Amyloidosis, paving the way for potential future breakthroughs in treatment options.